148 related articles for article (PubMed ID: 17293900)
1. Economic evaluation of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Vanni T
Braz J Infect Dis; 2006 Aug; 10(4):231. PubMed ID: 17293900
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Estes L; Orenstem R
Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Lyles A
Clin Ther; 2007 Feb; 29(2):384. PubMed ID: 17472833
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus.
Machado AR; Arns Cda C; Follador W; Guerra A
Braz J Infect Dis; 2005 Jun; 9(3):191-200. PubMed ID: 16224625
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Estes L; Orenstein R
Clin Ther; 2007 Feb; 29(2):381-3; author reply 383-4. PubMed ID: 17472831
[No Abstract] [Full Text] [Related]
6. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses.
Powers JH; Ross DB; Lin D; Soreth J
Chest; 2004 Jul; 126(1):314-5; author reply 315-6. PubMed ID: 15249482
[No Abstract] [Full Text] [Related]
7. Vancomycin for methicillin-resistant Staphylococcus aureus pneumonia: the good, the bad, and the ugly.
Kollef MH
Crit Care Med; 2012 Jan; 40(1):330-2. PubMed ID: 22179367
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
De Cock E; Krueger WA; Sorensen S; Baker T; Hardewig J; Duttagupta S; Müller E; Piecyk A; Reisinger E; Resch A
Infection; 2009 Apr; 37(2):123-32. PubMed ID: 19277465
[TBL] [Abstract][Full Text] [Related]
9. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Wunderink RG; Rello J; Cammarata SK; Croos-Dabrera RV; Kollef MH
Chest; 2003 Nov; 124(5):1789-97. PubMed ID: 14605050
[TBL] [Abstract][Full Text] [Related]
10. Methicillin-resistant Staphylococcus aureus pneumonia after thoracic surgery: successful treatment with linezolid after failed vancomycin therapy.
Salerno D; Vahid B; Marik PE
Ann Thorac Surg; 2007 May; 83(5):1888-91. PubMed ID: 17462428
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Segarra-Newnham M; Church TJ
Ann Pharmacother; 2012 Dec; 46(12):1678-87. PubMed ID: 23232021
[TBL] [Abstract][Full Text] [Related]
12. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Daniel Mullins C; Kuznik A; Shaya FT; Obeidat NA; Levine AR; Liu LZ; Wong W
Clin Ther; 2006 Aug; 28(8):1184-1198. PubMed ID: 16982296
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial.
Alaniz C; Pogue JM
Ann Pharmacother; 2012 Oct; 46(10):1432-5. PubMed ID: 22947593
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs.
Martinez-Olondris P; Rigol M; Soy D; Guerrero L; Agusti C; Quera MA; Li Bassi G; Esperatti M; Luque N; Liapikou M; Filella X; Marco F; de la Bellacasa JP; Torres A
Crit Care Med; 2012 Jan; 40(1):162-8. PubMed ID: 21926613
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis.
Bounthavong M; Zargarzadeh A; Hsu DI; Vanness DJ
Value Health; 2011; 14(5):631-9. PubMed ID: 21839399
[TBL] [Abstract][Full Text] [Related]
17. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin.
Shorr AF; Susla GM; Kollef MH
Crit Care Med; 2004 Jan; 32(1):137-43. PubMed ID: 14707572
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.
Patanwala AE; Erstad BL; Nix DE
Curr Med Res Opin; 2007 Jan; 23(1):185-93. PubMed ID: 17257479
[TBL] [Abstract][Full Text] [Related]
19. Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Patel DA; Shorr AF; Chastre J; Niederman M; Simor A; Stephens JM; Charbonneau C; Gao X; Nathwani D
Crit Care; 2014 Jul; 18(4):R157. PubMed ID: 25053453
[TBL] [Abstract][Full Text] [Related]
20. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
Chastre J; Blasi F; Masterton RG; Rello J; Torres A; Welte T
Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():19-36. PubMed ID: 24580739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
